​

Enliven Therapeutics Ownership | Who Owns Enliven Therapeutics?

OverviewForecastFinancialsChart

Enliven Therapeutics Ownership Summary

Enliven Therapeutics is owned by 17.61% institutional investors, 8.21% insiders, and 74.18% retail investors. Orbimed advisors is the largest institutional shareholder, holding 15.28% of ELVN shares.

ELVN Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockEnliven Therapeutics17.61%8.21%74.18%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Orbimed advisors7.96M15.28%$162.93M
Fmr7.13M13.68%$145.93M
Commodore capital lp4.69M9.01%$96.06M
Fairmount funds management3.71M7.12%$75.97M
Blackrock funding, inc. /de3.52M6.75%$72.02M
Vr adviser3.23M6.19%$66.04M
Polar capital3.10M5.94%$63.35M
Vanguard group2.55M4.90%$52.26M
Novo1.43M2.74%$29.20M
Blackstone1.32M2.53%$27.03M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Fairmount funds management3.71M6.84%$75.97M
5am venture management772.48K5.79%$15.81M
Commodore capital lp4.69M4.69%$96.06M
Orbimed advisors7.96M3.84%$162.93M
Vr adviser3.23M3.72%$66.04M
First turn management783.41K2.41%$16.04M
Novo1.43M1.88%$29.20M
Patient square capital lp250.84K1.37%$5.13M
Highvista strategies259.13K1.30%$5.30M
Caxton13.10K1.17%$268.11K

Top Buyers

HolderShares% AssetsChange
Vestal point capital, lp1.16M1.07%910.00K
Blackrock funding, inc. /de3.52M0.00%551.39K
Duquesne family office947.40K0.48%484.40K
Novo1.43M1.88%341.83K
First turn management783.41K2.41%273.42K

Top Sellers

HolderShares% AssetsChange
Ra capital management---848.99K
Woodline partners lp300.50K0.03%-800.16K
Vr adviser3.23M3.72%-800.00K
Tcg crossover management---498.00K
Fmr7.13M0.01%-430.70K

New Positions

HolderShares% AssetsChangeValue
Pfm health sciences, lp156.46K0.25%156.46K$3.20M
Squarepoint ops35.84K0.00%35.84K$733.75K
Connor, clark & lunn investment management34.78K0.00%34.78K$711.93M
Winton group16.46K0.01%16.46K$336.89K
Man group13.37K0.00%13.37K$273.70K

Sold Out

HolderChange
Td capital management-16.00
Stephens consulting-20.00
Amundi-23.00
Clear street markets-76.00
Capital advisors-302.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202552-57.72%9,174,149-84.56%170.14%34-58.02%10-56.52%
Jun 30, 20251220.83%59,425,06519.12%1141.14%8023.08%23-30.30%
Mar 31, 202514-87.27%19,292,189-60.47%380.38%5-92.19%3-88.00%
Dec 31, 20241129.80%49,623,7144.06%1021.05%6611.86%254.17%
Sep 30, 20241028.51%47,688,348-1.31%980.98%59-14.49%2484.62%

Recent Insider Transactions

DateNameRoleActivityValue
Nov 19, 2025Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICERSell$267.79K
Nov 19, 2025Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICERSell$11.36K
Nov 17, 2025Kintz Samuel PRESIDENT AND CEOSell$272.74K
Nov 07, 2025Patel Anish CHIEF OPERATING OFFICERSell$11.00K
Nov 07, 2025Patel Anish CHIEF OPERATING OFFICERSell$105.04K

Insider Transactions Trends

DateBuySell
2025 Q4-8
2025 Q3-28
2025 Q2-28
2025 Q1-14
2024 Q4-34

ELVN Ownership FAQ

Who Owns Enliven Therapeutics?

Enliven Therapeutics shareholders are primarily institutional investors at 17.61%, followed by 8.21% insiders and 74.18% retail investors. The average institutional ownership in Enliven Therapeutics's industry, Biotech Stocks , is 45.24%, which Enliven Therapeutics falls below.

Who owns the most shares of Enliven Therapeutics?

Enliven Therapeutics’s largest shareholders are Orbimed advisors (7.96M shares, 15.28%), Fmr (7.13M shares, 13.68%), and Commodore capital lp (4.69M shares, 9.01%). Together, they hold 37.96% of Enliven Therapeutics’s total shares outstanding.

Does Blackrock own Enliven Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Enliven Therapeutics.

Who is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested?

Fairmount funds management is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.84% of its assets in 3.71M Enliven Therapeutics shares, valued at 75.97M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools